BUZZ-Indivior: hits record on raised FY revenue forecast

** Indivior (LSE: INDV.L - news) 's shares up 12.8 pct at all-time high & easily top FTSE 250 gainer

** Co, which makes opioid addiction treatment drugs, raises FY revenue forecast to $1-$1.3 bln from $945-$975 mln after strong H1 results

** Jefferies sees continued high/mid single-digit growth for buprenorphine market (Suboxone Film, Indivior's main product, is the commercial name for buprenorphine/naloxone combination)

** Legislation in US to increase number of patients that can be treated by a doctor for opioid problems is an indication of strong support for tackling opioid epidemic, per Jefferies

** Co says H1 net rev up 3 pct to $531 mln on strong sales, higher rebates in the US & slightly increased market share

** Up to Thursday's close, stock +45 pct v +13.8 pct on FTSE 350 Pharmaceuticals & Biotechnology Index (albeit after ~50 pct drop for stock from July 2015 peak until May 2016 low)

** Best day since early June when co won a patent ruling on Suboxone Film (shares leapt 36% OTD)